43% CR/CRi/CRp rate with bemcentinib monotherapy reported in AXL biomarker positive R/R AML/MDS patients (6 out of 14) Phase II trial continues in combination with chemotherapeutics in first line AML Bemcentinib with decitabine cohort has completed recruitment, data...
The Cancer Research Institute (CRI), a nonprofit organization dedicated to the discovery and development of powerful immunotherapies for all cancers, announced today the publication of a report that provides a comprehensive analysis of the current clinical trial...
QPS, a GLP/GCP-compliant contract research organization (CRO) supporting discovery, preclinical and clinical drug development, today announced the expansion of its U.S.-based Phase I clinical trial capabilities to support the growing needs of its pharmaceutical,...
PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for orphan diseases, with an initial focus on cardiopulmonary disorders, today announced that the first patient in a Phase 2b...
Initiation of Phase 1/2 Combination Clinical Trial with Evelo’s Monoclonal Microbial, EDP1503, and KEYTRUDA® (pembrolizumab) Across Various Indications Expected in First Half of 2019 Evelo Biosciences, Inc.. a clinical-stage biotechnology company developing monoclonal...
Email
Text